Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Anxiety
Bipolar Disorder
Depression
Emerging Approaches in Schizophrenia
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
View All
Juan-Manuel Anaya, MD, PhD
a:1:{i:0;s:69:"Universidad de la Costa, Faculty of Medicine, Barranquilla, Colombia";}
JCP
Original Research
Vortioxetine for Cognitive Impairment in MDD Post-COVID
May 5, 2025
Measures of cognitive function and depressive symptoms improved to a greater extent with vortioxetine than with escitalopram or sertraline in post-COVID syndrome participants with MDD.
Hernan F. Guillen-Burgos
,
Juan F. Galvez-Florez
,
Sergio Moreno-López
, et al